IRIS
GERETTI, ANNA MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.858
AS - Asia 4.609
EU - Europa 1.485
Continente sconosciuto - Info sul continente non disponibili 858
SA - Sud America 751
AF - Africa 80
OC - Oceania 6
Totale 15.647
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.595
SG - Singapore 1.892
HK - Hong Kong 862
CN - Cina 659
BR - Brasile 604
RU - Federazione Russa 421
IT - Italia 400
VN - Vietnam 360
BD - Bangladesh 319
JP - Giappone 278
FI - Finlandia 144
GB - Regno Unito 100
CA - Canada 97
DE - Germania 82
FR - Francia 80
IN - India 67
MX - Messico 62
AR - Argentina 55
SE - Svezia 55
UA - Ucraina 35
ID - Indonesia 31
JM - Giamaica 29
CR - Costa Rica 28
NL - Olanda 28
CO - Colombia 27
AT - Austria 25
ZA - Sudafrica 25
IE - Irlanda 24
PL - Polonia 21
EC - Ecuador 20
PK - Pakistan 18
ES - Italia 17
IR - Iran 16
IQ - Iraq 14
CH - Svizzera 13
TR - Turchia 13
PY - Paraguay 12
VE - Venezuela 12
HN - Honduras 11
TN - Tunisia 10
AZ - Azerbaigian 9
CL - Cile 9
EG - Egitto 8
KR - Corea 8
NI - Nicaragua 8
TT - Trinidad e Tobago 8
AE - Emirati Arabi Uniti 7
EE - Estonia 7
MA - Marocco 7
PE - Perù 7
SA - Arabia Saudita 7
JO - Giordania 6
MY - Malesia 6
AU - Australia 5
KE - Kenya 5
MW - Malawi 5
UY - Uruguay 5
UZ - Uzbekistan 5
BB - Barbados 4
ET - Etiopia 4
IL - Israele 4
LT - Lituania 4
OM - Oman 4
PH - Filippine 4
TH - Thailandia 4
AL - Albania 3
CM - Camerun 3
DO - Repubblica Dominicana 3
GR - Grecia 3
HR - Croazia 3
NP - Nepal 3
RO - Romania 3
SK - Slovacchia (Repubblica Slovacca) 3
BE - Belgio 2
BG - Bulgaria 2
CG - Congo 2
DK - Danimarca 2
DZ - Algeria 2
GD - Grenada 2
GH - Ghana 2
HU - Ungheria 2
LB - Libano 2
LC - Santa Lucia 2
MT - Malta 2
SN - Senegal 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
ZW - Zimbabwe 2
AG - Antigua e Barbuda 1
AM - Armenia 1
BN - Brunei Darussalam 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BS - Bahamas 1
BZ - Belize 1
CI - Costa d'Avorio 1
CU - Cuba 1
GT - Guatemala 1
IS - Islanda 1
Totale 14.779
Salva come PNG Salva come JPEG
Città #
San Jose 1.107
Hong Kong 844
Ashburn 681
Singapore 661
Woodbridge 566
Houston 512
Council Bluffs 509
Wilmington 477
Tokyo 273
Los Angeles 195
Beijing 167
The Dalles 146
Ho Chi Minh City 121
Buffalo 119
Helsinki 114
New York 114
Dallas 109
Redondo Beach 99
Fairfield 76
Santa Clara 74
Hanoi 70
Chicago 69
Moscow 67
Rome 60
Ann Arbor 56
Phoenix 44
Seattle 41
Mexico City 40
Milan 38
São Paulo 37
North Bergen 34
Cambridge 31
Lauterbourg 30
Denver 29
Atlanta 27
Jacksonville 26
Salt Lake City 23
Dublin 22
Lappeenranta 22
Boardman 21
Orem 19
Philadelphia 19
Naples 18
San José 18
Haiphong 17
Brooklyn 15
Frankfurt am Main 15
Kingston 15
Miami 15
Tehran 15
Brasília 14
Elk Grove Village 14
Johannesburg 14
Medford 14
Montreal 14
Nuremberg 14
Queens 14
Rio de Janeiro 14
Chandler 13
Kraków 13
Stockholm 13
Da Nang 12
Dearborn 12
London 12
Shaoxing 12
Amsterdam 11
Belo Horizonte 11
San Francisco 11
Bologna 10
Genoa 10
New Orleans 10
Changsha 9
Florence 9
Hefei 9
Newark 9
Sacramento 9
Sterling 9
Vienna 9
Baku 8
Bari 8
Boston 8
Charlotte 8
Columbus 8
Guarulhos 8
Managua 8
Quito 8
Ribeirão Preto 8
Salvador 8
Staten Island 8
Tampa 8
The Bronx 8
Toronto 8
Turin 8
Washington 8
Zhengzhou 8
Biên Hòa 7
Bogotá 7
Chennai 7
Dulles 7
Fort Wayne 7
Totale 8.413
Salva come PNG Salva come JPEG
Nome #
European guidelines on the clinical management of HIV-1 tropism testing 472
When and how to use maraviroc in HIV-infected patients 466
Emerging patterns and implications of HIV-1 integrase inhibitor resistance 421
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: A multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing 417
Optimal use of maraviroc in clinical practice 395
The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis 294
Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants 267
Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy 213
Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution 209
2024 European guidelines for the management of genital herpes 198
Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: A cross-sectional comparison with the general population 142
Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV infection 114
A contaminant-free assessment of Endogenous Retroviral RNA in human plasma 93
Plasma HIV-1 RNA detection below 50 copies/mL and risk of virologic rebound in patients receiving highly active antiretroviral therapy 93
The evolving landscape of COVID-19: Factors associated with in-hospital COVID-19 related mortality during the 2023-2024 phase of JN.1 subvariant dominance 92
A detailed characterization of drug resistance during darunavir/ritonavir monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance 89
A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action 88
Diagnostic performance evaluation of hepatitis B e antigen rapid diagnostic tests in Malawi 88
British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015 87
Safety, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide RO7239958 in healthy volunteers and adults with chronic hepatitis B infection 85
Epidemiology of hepatitis B, C and D in Malawi: Systematic review 11 Medical and Health Sciences 1117 Public Health and Health Services 11 Medical and Health Sciences 1108 Medical Microbiology 11 Medical and Health Sciences 1103 Clinical Sciences 83
Research news in clinical context 82
The intrahepatic activity of Hepatitis Delta virus is sustained by an abundant production of HBs transcripts, mainly derived from integrated HBV-DNA, and is not strictly related to the extent of HBV reservoir 80
Liver Fibrosis by Transient Elastography and Virologic Outcomes after Introduction of Tenofovir in Lamivudine-Experienced Adults with HIV and Hepatitis B Virus Coinfection in Ghana 79
Alcohol, smoking, recreational drug use and association with virological outcomes among people living with HIV: cross-sectional and longitudinal analyses 79
Chronic HDV infection is sustained by an intense HBsAg production fromintegrated HBVDNA in the setting of a limited or even absent HBV reservoir. 76
PATHWAYS UNDERLYING HDV PERSISTENCE ACT INDEPENDENTLY FROM THE EXTENT OF HBV RESEVOIR AND ARE SUSTAINED BY AN ABUNDANT PRODUCTION OF HBSAG DERIVED FROM INTEGRATED HBV-DNA P 214 76
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process 75
Determining virological suppression and resuppression by point-of-care viral load testing in a HIV care setting in sub-Saharan Africa 74
Age, time living with diagnosed HIV infection, and self-rated health 74
Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study 73
A clinical and molecular epidemiological survey of hepatitis C in Blantyre, Malawi, suggests a historic mechanism of transmission 71
A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-na{\"i}ve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): Study protocol for a randomised trial 71
Safety and pharmacokinetic characterization of nacubactam, a novel ?-lactamase inhibitor, alone and in combination with meropenem, in healthy volunteers 69
Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom 69
Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data 68
Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression 67
Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance- a phase IV randomised, open-label study (PIBIK study). 67
HBsAg production from integrated HBV-DNA sustains HDV persistence in the setting of a limited or even absent HBV reservoir 67
Factors associated with persistence of plasma HIV-1 RNA during long-term continuously suppressive firstline antiretroviral therapy 67
Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis 66
HDV persistence is sustained by HBsAg mainly derived from integrated HBV-DNA and is independent from the extent of HBV reservoir 66
Pathways sustaining HDV activity act independently from the size of HBV resevoir and are fueled by an abundant expression of HBsAg from integrated HBV-DNA 64
Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy 63
Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia 62
Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIVPositive adults receiving first-line antiretroviral therapy in Malawi 62
Causes, associated exposures, and outcomes of cirrhosis and hepatocellular carcinoma in Malawi: an observational cohort and case–control study 62
HLA-A is a Predictor of Hepatitis B e Antigen Status in HIV-Positive African Adults 62
A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients 60
Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation 60
Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment 60
Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey 60
HIV-1 subtypes: Epidemiology and significance for HIV management 60
Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK 59
Primary herpes simplex virus type-2 infection as a cause of liver failure after liver transplantation 59
Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: Results from the cross-sectional ASTRA study 59
Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study 59
The gamma-glutamyl transpeptidase to platelet ratio (GPR) shows poor correlation with transient elastography measurements of liver fibrosis in HIV-positive patients with chronic hepatitis B in West Africa. Response to: {'}The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa{'} by Lemoine et al 58
2017 European guidelines for the management of genital herpes 58
Accuracy of self-report of HIV viral load among people with HIV on antiretroviral treatment 58
Attitudes of people in the UK with HIV who are antiretroviral (ART) na{\"i}ve to starting art at high CD4 counts for potential health benefit or to prevent HIV transmission 58
During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQ 58
The burden of HDV chronic infection and the gaps in HDV screening across Europe: an urgent need to strengthen diagnostic strategies at pan-European level 57
An apparent paradox: Resistance mutations in HIV-1 DNA predict improved virological responses to antiretroviral therapy 57
Kinetics and Specificities of the T Helper?Cell Response to GP120 in the Asymptomatic Stage of HIV-1 Infection 57
Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades 57
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook 57
Efficacy of once daily darunavir/ritonavir in PI-Na{\"i}ve, NNRTI-experienced patients in the ODIN trial 56
Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection 56
Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia 55
A virological perspective on resistance in highly treatment-experienced patients 54
Hepatitis B virus infection in general practice across England: An analysis of the Royal College of General Practitioners Research and Surveillance Centre real-world database 54
Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz 54
Antibody screening tests variably overestimate the prevalence of hepatitis C virus infection among HIV-infected adults in Ghana 54
2014 European guideline on HIV testing 53
Measuring Proviral HIV-1 DNA: Hurdles and Improvements to an Assay Monitoring Integration Events Utilising Human Alu Repeat Sequences 53
Real-world prevalence of non-integrase INSTI resistance-associated mutations and virological outcomes in people who have recently acquired HIV-1 in the UK 53
HBV-RNA Co-amplification May Influence HBV DNA Viral Load Determination 53
Socioeconomic status and treatment outcomes for individuals with HIV on antiretroviral treatment in the UK: cross-sectional and longitudinal analyses 53
IAPAC guidelines for optimizing the HIV care continuum for adults and adolescents 53
Renal health after long-term exposure to tenofovir disoproxil fumarate (TDF) in HIV/HBV positive adults in Ghana 52
Occult hepatitis B virus coinfection in HIV-positive African migrants to the UK: A point prevalence study 52
Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring 52
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight) 52
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: A systematic review and pooled analysis 52
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 51
Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation 51
COVID-19 and influenza vaccination among adults stably engaged in HIV care 51
Emergent Human Immunodeficiency Virus Type 1 (HIV-1) Drug Resistance in Randomized Trials of Contemporary Antiretroviral Regimens 51
Liver steatosis and fibrosis in people with human immunodeficiency virus in West Africa and the relationship with hepatitis B virus coinfection 51
Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions 51
Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection 51
HIV DNA Sequencing to Detect Archived Antiretroviral Drug Resistance 50
Prospective pilot study on the relationship between seminal HIV-1 shedding and genital schistosomiasis in men receiving antiretroviral therapy along Lake Malawi 50
Point-of-Care Screening for a Current Hepatitis C Virus Infection: Influence on Uptake of a Concomitant Offer of HIV Screening 50
Detection of highly prevalent hepatitis B virus coinfection among HIV-seropositive persons in Ghana 50
Comparative performance of the new Aptima HIV-1 Quant Dx assay with three commercial PCR-based HIV-1 RNA quantitation assays 50
Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5) 50
Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study 50
Antiretroviral resistance in clinical practice 49
Totale 9.125
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.652
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.652
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202260 0 0 0 2 1 8 3 7 15 4 4 16
2022/202357 8 0 0 6 4 20 6 2 5 0 6 0
2023/202419 3 0 0 0 0 2 0 0 0 10 0 4
2024/20253.043 6 36 28 10 3 59 67 716 886 271 575 386
2025/20267.419 503 473 864 441 413 177 692 1.029 1.145 635 723 324
2026/20273.129 470 516 1.526 617 0 0 0 0 0 0 0 0
Totale 15.647